Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology

Chronic Lymphocytic Leukemia

Arizona

Peoria : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

California

Duarte : City of Hope

A Phase II Multicenter Trial of Myeloablative Double Unit Umbilical Cord Blood Transplantation (UCBT) in Adults with Hematologic Malignancy

Duarte : City of Hope

SWOG 9007: Cytogenetic Studies In Leukemia Patients

La Jolla : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Los Angeles : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Sacramento : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Sacramento : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Colorado

Denver : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Florida

Fort Meyers : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Hialeah : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Illinois

Chicago : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Chicago : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Chicago : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Chicago : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Hines : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Indiana

Beach Grove : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Beech Grove : St. Francis Hospital and Health Centers

Lumiliximab With Fludarabine,Cyclophosphamide,and Rituximab(FCR)Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia(CLL) (LUCID)

Kansas

Overland Park : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Louisiana

Shreveport : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Massachusetts

Boston : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Michigan

Ann Arbor : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Detroit : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Detroit : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Yosilanti : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Yosilanti : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Missouri

Saint Louis : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

New Jersey

Hackensack : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Newark : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

New York

East Syracuse : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

New Hyde Park : Biomedical Research Alliance of New York

Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (CLL) Adults

New York : Weill Cornell Medical College

A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients with Select, Relapsed or Refractory Hematologic Malignancies

New York : Weill Cornell Medical College

A Phase I/II Multi-Center, Open-Label Study of the Safety and Efficacy of a Stepwise Dose-Escalation Schedule of Lenalidomide Monotherapy in Subjects With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

New York : Weill Cornell Medical College

Phase II Study of Forodesine in Subjects with Chronic Lymphocytic Leukemia (CLL)

Rochester : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

North Carolina

Chapel Hill : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Raleigh : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Pennsylvania

Philadephia : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Pittsburgh : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Rhode Island

Providence : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

South Carolina

Greenville : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Tennessee

Nashville : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Texas

Bedford : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Dallas : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Fort Worth : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Houston : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Houston : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

San Antonio : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Virginia

Roanoke : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Washington

Perth : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Seattle : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Seattle : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Spokane : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Yakima : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Australia

Adelaide : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Adelaide, SA : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Ashford : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Box Hill, VIC : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Brisbane : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Clayton : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Clayton, VIC : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Coburg, VIC : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Fitzroy, VIC : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Freemantle : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Gosford : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Greenslopes, QLK : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Nedlands : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

South Granville : Merck Sharp & Dohme (Australia) Pty Ltd.

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

St. Leonards : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Waratah : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Westmead : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Westmead, NSW : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Woodville : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Woolloongabba : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Austria

Graz : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Graz : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Herston : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Wien : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Wien : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Wien : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Wien : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Belgium

Antwerpen : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Antwerpen : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Brugge : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Brussels : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Bruxelles : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Bruzelles : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Edegem : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Gent : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Leuven : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Mont-Godinne : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Roeselare : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Wilrijk : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Yvoir : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Canada

Edmonton : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

London : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Ottawa, ON : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Toronto : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

France

Angers : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Angers : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Bordeaux : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Bordeaux : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Le Mans : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Le Mans : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Lillie : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Limoges : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Limoges : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Nice : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Nice : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Paris : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Pessac : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Pierre Benite : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Rennes : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Strasbourg : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Italy

Bologna : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Bologna : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Cagliari : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Milano : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Poland

Bialystok : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Bialystok : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Gdansk : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Gdansk : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Katowice : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Krakow : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Lodz : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Lodz : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Szczecin : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Warszawa : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Romania

Brasov : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Bucharest : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Iasi : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Russian Federation

Ekaterinburg : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Nizhni Novgorod : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Obninsk : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Samara : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Saratov : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

St. Petersburg : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Spain

Madrid : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Madrid : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Murcia : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Palma de Mallorca : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Salamanca : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Toledo : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Toledo : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

United Kingdom

Bath : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Exeter : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Leeds : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

London : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

London : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

London : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Plymouth : Biogen Idec, Inc.

Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Plymouth : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)

Plymouth : Research Site

Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)